Historical record - last NADAC effective date: 9/22/2021
Product Information
AMLODIPINE-BENAZEPRIL 5-40 MG is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $0.1546 per EA under NDC 68180075901. Its NADAC has been published 411 times since Nov 28, 2013.
FDA first approved this application on Feb 5, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5; 40 mg/1; mg/1
Manufacturer
Lupin Pharmaceuticals Inc.NDC
68180075901
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/22/2021
Active Ingredients
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA078466FDA Approved
2/5/2010
TE Code
AB
On Market Since
7/5/2011
Pharmacological Classes
Price Statistics
The NADAC for AMLODIPINE-BENAZEPRIL 5-40 MG has been published 411 times since Nov 28, 2013, and over the history we have for it it has declined 72.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1546 per EA |
|---|---|
| All-time high | $0.5822 (Feb 12, 2014) |
| All-time low | $0.1267 (Jan 23, 2019) |
| Median price | $0.2360 |
| Average price | $0.2697 |
| Largest weekly change | -34.6% (Aug 22, 2018) |
| Weeks tracked | 411 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
-72.6%
Last surveyed Oct 6, 2021 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 7% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Amlodipine Besylate and Benazepril Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin Converting Enzyme Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AMLODIPINE-BENAZEPRIL 5-40 MG?
The current National Average Drug Acquisition Cost (NADAC) for AMLODIPINE-BENAZEPRIL 5-40 MG, manufactured by Lupin Pharmaceuticals Inc., is $0.1546 per EA (NDC 68180075901), effective Oct 6, 2021.
How has the price of AMLODIPINE-BENAZEPRIL 5-40 MG changed over time?
Over the history we have for it, the NADAC for AMLODIPINE-BENAZEPRIL 5-40 MG has declined 72.6%. It has been tracked across 411 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for AMLODIPINE-BENAZEPRIL 5-40 MG?
Since Nov 28, 2013, the NADAC for AMLODIPINE-BENAZEPRIL 5-40 MG has ranged from a low of $0.1267 (Jan 23, 2019) to a high of $0.5822 (Feb 12, 2014), with a median of $0.2360 per EA.
Are there cheaper alternatives to AMLODIPINE-BENAZEPRIL 5-40 MG?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, AMLODIPINE-BENAZEPRIL 5-40 MG, is $0.1439 per EA — about 7% below AMLODIPINE-BENAZEPRIL 5-40 MG.
Who manufactures AMLODIPINE-BENAZEPRIL 5-40 MG?
AMLODIPINE-BENAZEPRIL 5-40 MG (NDC 68180075901) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.